Will FDA Inspection Observations Fog Speculated Claris Deal?

Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with chatter about a deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.

MUMBAI – India’s Claris Injectables Ltd. has been served five inspectional observations by the U.S. Food and Drug Administration for its Chacharvadi-based facility near Ahmedabad following an inspection between May 4 and 11.

The four-page report addressed to Claris Chairman Arjun Handa cites issues such as incomplete data in laboratory records derived from tests, examinations and assays necessary to assure compliance with established...

More from India

More from Asia